Febuxostat, an Inhibitor of Xanthine Oxidase, Suppresses Lipopolysaccharide-Induced MCP-1 Production via MAPK Phosphatase-1-Mediated Inactivation of JNK

• Johji Nomura ,

  * E-mail: j.nomura@teijin.co.jp

  Affiliation Pharmaceutical Department Research Laboratories, Teijin Institute for Bio-Medical Research, Teijin Pharma Limited, Hino, Tokyo, Japan

  ⨯
• Nathalie Busso,

  Affiliation Service of Rheumatology, Department of l’Appareil Locomoteur, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland

  ⨯
• Annette Ives,

  Affiliation Service of Rheumatology, Department of l’Appareil Locomoteur, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland

  ⨯
• Syunsuke Tsujimoto,

  Affiliation Pharmaceutical Department Research Laboratories, Teijin Institute for Bio-Medical Research, Teijin Pharma Limited, Hino, Tokyo, Japan

  ⨯
• Mizuho Tamura,

  Affiliation Pharmaceutical Department Research Laboratories, Teijin Institute for Bio-Medical Research, Teijin Pharma Limited, Hino, Tokyo, Japan

  ⨯
• Alexander So,

  Affiliation Service of Rheumatology, Department of l’Appareil Locomoteur, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland

  ⨯
• Yoshihiro Yamanaka

  Affiliation Pharmaceutical Department Research Laboratories, Teijin Institute for Bio-Medical Research, Teijin Pharma Limited, Hino, Tokyo, Japan

  ⨯